Advances in Islet Transplantation and the Future of Stem Cell-Derived Islets to Treat Diabetes.
| Autor: | Kieffer TJ; Department of Cellular and Physiological Sciences, Life Sciences Institute, School of Biomedical Engineering, Vancouver V6T1Z3, British Columbia, Canada tim.kieffer@ubc.ca.; Department of Surgery, The University of British Columbia, Vancouver V6T1Z3, British Columbia, Canada., Hoesli CA; Department of Chemical Engineering, McGill University, Montreal H3A 0C5, Québec, Canada.; Associate Member, Department of Biomedical Engineering, McGill University, Montreal H3A 0C5, Québec, Canada., Shapiro AMJ; Clinical Islet Transplant Program, University of Alberta, Edmonton T6G2E1, Alberta, Canada.; Department of Surgery, University of Alberta, Edmonton T6G2E1, Alberta, Canada.; Alberta Diabetes Institute, University of Alberta, Edmonton T6G2E1, Alberta, Canada. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cold Spring Harbor perspectives in medicine [Cold Spring Harb Perspect Med] 2024 Jul 29. Date of Electronic Publication: 2024 Jul 29. |
| DOI: | 10.1101/cshperspect.a041624 |
| Abstrakt: | β-Cell replacement for type 1 diabetes (T1D) can restore normal glucose homeostasis, thereby eliminating the need for exogenous insulin and halting the progression of diabetes complications. Success in achieving insulin independence following transplantation of cadaveric islets fueled academic and industry efforts to develop techniques to mass produce β cells from human pluripotent stem cells, and these have now been clinically validated as an alternative source of regulated insulin production. Various encapsulation strategies are being pursued to contain implanted cells in a retrievable format, and different implant sites are being explored with some strategies reaching clinical studies. Stem cell lines, whether derived from embryonic sources or reprogrammed somatic cells, are being genetically modified for designer features, including immune evasiveness to enable implant without the use of chronic immunosuppression. Although hurdles remain in optimizing large-scale manufacturing, demonstrating efficacy, durability, and safety, products containing stem cell-derived β cells promise to provide a potent treatment for insulin-dependent diabetes. (Copyright © 2024 Cold Spring Harbor Laboratory Press; all rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|